Showing results (101-110 of 111) with videos related to

Sort By:
Pageof 12
Nature Chemical Biology|November 2, 2021
Post-translational insertion of boron in proteins to probe and modulate functionTim A Mollner, Patrick G Isenegger, Brian Josephson, et al.
Scientific Reports|April 15, 2017
Interplay of buried histidine protonation and protein stability in prion misfoldingAnatoly Malevanets, P Andrew Chong, D Flemming Hansen, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|July 2, 2024
The Influence of Disulfide, Thioacetal and Lanthionine-Bridges on the Conformation of a Macrocyclic PeptideWilliam T P Darling, Lianne H E Wieske, Declan T Cook, et al.
Nature Communications|August 2, 2020
A distal regulatory region of a class I human histone deacetylaseNicolas D Werbeck, Vaibhav Kumar Shukla, Micha B A Kunze, et al.
Biophysical Journal|July 28, 2019
Interaction Between the a3 Region of Factor VIII and the TIL'E' Domains of the von Willebrand FactorLisbeth Dagil, Kathrin S Troelsen, Gert Bolt, et al.
Cell Reports|February 27, 2020
Mechanism of Crosstalk between the LSD1 Demethylase and HDAC1 Deacetylase in the CoREST ComplexYun Song, Lisbeth Dagil, Louise Fairall, et al.
Nature Communications|August 17, 2016
miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cellsMads Heilskov Rasmussen, Iben Lyskjær, Rosa Rakownikow Jersie-Christensen, et al.
Molecular Oncology|March 20, 2013
High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancerMads H Rasmussen, Niels F Jensen, Line S Tarpgaard, et al.
Nature Catalysis|October 27, 2025
Methylthio-alkane reductases use nitrogenase metalloclusters for carbon-sulfur bond cleavageAna Lago-Maciel, Jéssica C Soares, Jan Zarzycki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2012
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII studyKjell Magne Tveit, Tormod Guren, Bengt Glimelius, et al.
Pageof 12